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Abstract
Objective: The latest nonnucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine (RPV) is indicated for
human immunodeficiency virus type-1 (HIV-1) patients initiating antiretroviral treatment, but the extent of
genotypic RPV resistance in treatment-naive patients outside clinical trials is poorly defined.
Study Design: This retrospective observational study of clinical data from Belgium and Portugal evaluates ge-
notypic information from HIV-1 drug-naive patients obtained for the purpose of drug resistance testing. Rilpivirine
resistance-associated mutations (RPV-RAMs) were defined based on clinical trials, phenotypic studies, and expert-
based resistance algorithms. Viral susceptibility to RPV alone and to the single-tablet regimen was estimated using
expert-based resistance algorithms.
Results: In 4,631 HIV-1 treatment-naive patients infected with diverse HIV-1 subtypes, major RPV-RAMs were
detected in 4.6%, while complete viral susceptibility to RPV was estimated in 95% of patients. Subtype C- and F1-
infected patients displayed the highest levels of reduced viral susceptibility at baseline, respectively 13.2% and
9.3%, mainly due to subtype- and geographic-dependent occurrence of RPV-RAMs E138A and A98G as natural
polymorphisms. Strikingly, a founder effect in Portugal resulted in a 138A prevalence of 13.2% in local subtype C-
infected treatment-naive patients. The presence of transmitted drug resistance did not impact our estimates.
Conclusion: RPV is the first HIV-1 inhibitor for which, in the absence of transmitted drug resistance, intermediate
or high-level genotypic resistance can be detected in treatment-naive patients. The extent of RPV susceptibility in
treatment-naive patients differs depending on the HIV-1 subtype and dynamics of local compartmentalized epi-
demics. The highest prevalence of reduced susceptibility was found to be 15.7% in Portuguese subtype C-infected
treatment-naive patients. In this context, even in the absence of transmitted HIV-1 drug resistance (TDR), drug
resistance testing at baseline should be considered extremely important before starting treatment with this NNRTI.
Introduction
R ilpivirine (RPV) is the latest nonnucleoside reversetranscriptase (RT) inhibitor (NNRTI) approved for an-
tiretroviral treatment (ART) of human immunodeficiency
virus type-1 (HIV-1) infection. RPV is currently indi-
cated for treatment-naive patients with a viral load lower
than 100,000 copies/mL,1 and predominantly adminis-
tered first-line as a single-tablet regimen (STR) with a
fixed-dose coformulation containing nucleos(t)ide RT
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inhibitors (NRTIs) tenofovir disoproxil fumarate (TDF)
and emtricitabine (FTC).
While the phase 3 clinical studies ECHO and THRIVE
demonstrated noninferior virological efficacy and safety of
RPV compared to efavirenz,2,3 these clinical studies precluded
HIV-1 patients showing NNRTI mutations at baseline.
Although a low prevalence of RPV resistance-associated
mutations (RAMs) was described outside these clinical trials,
RPV-RAMs have been reported to occur naturally as poly-
morphisms, indicating an impact ofHIV-1 subtype on the RPV
activity.4–6 In this study, we evaluate the genotypic resistance
profile of RPV in a large database with HIV-1 genetic se-
quences of treatment-naive patients infected with different
subtypes. Viral susceptibility predictions were used to better
understand the clinical benefit of RPV for first-line HIV-1
treatment.
Materials and Methods
Clinical data of HIV-1 treatment-naive patients pooled from
a large HIV-1 drug resistance database in Portugal (n= 4,541)
and from the University Hospitals Leuven in Belgium
(n= 777), obtained for the purpose of routine genotypic re-
sistance testing before cART initiation, were retrospectively
examined.7,8 The study protocol was conducted in accordance
with the Declaration of Helsinki and approved by the ethics
committees of UZ Leuven (B322201420270/S56109) and
Centro Hospitalar de Lisboa Ocidental (108/CES-2014). For
each patient, the first available viral isolate spanning the RT
region was collected. HIV-1 subtype was assigned by Rega
V39 and COMET10 subtyping tools, and only the most prev-
alent subtypes concordantly determined by both tools were
retained for the final analysis, thereby excluding 687 patients.
As a result, the analysis was performed on 4,631 patients (715
from Belgium and 3,916 from Portugal).
Major RPV resistance-associated mutations (RPV-RAMs)
were defined based on data from the clinical trials, phenotypic
RPV resistance analyses, and package inserts: K101E/P,
E138A/G/K/Q/R,V179L,Y181C/I/V,Y188L,H221Y, F227C,
M230I/L, and the mutational combination of L100I+
K103N.1,11,12 In addition, we defined a list of minor RPV-
RAMs that have been observed in in vitro or in vivo selection
studies and are included in one or more of clinically widely
used genotypic resistance interpretation algorithms ANRS
(V24), Rega (V9.1.0), and HIVdb (V7.0.1),1–16 encompass-
ing V90I, A98G, L100I/V, K101H/Q/T, K103R/S, V106A/I,
V108I, E138S, V179D/E/F/I/T, Y181F/G/S, Y188F, V189I,
G190A/C/E/Q/S/T/V, and M230V.
Clinical implications of observed RPV genotypic resis-
tance were assessed by classifying viral isolates as suscep-
tible, intermediate resistant, or high-level resistant according
to Rega and HIVdb, and susceptible or resistant according to
ANRS. For HIVdb, five-level scores were simplified to three
levels: susceptible and potential low-level resistant were
scored as susceptible, low-level and intermediate resistant
were scored as intermediate resistant, and high-level resistant
as resistant. An estimate of preserved viral susceptibility was
obtained by averaging over the three algorithms. The activity
of the RPV-containing STR was also assessed by estimating
viral susceptibility to NRTIs TDF and FTC.
Evidence of transmitted HIV-1 drug resistance (TDR) was
defined by the presence of at least one surveillance drug
resistance mutation (SDRM) from the consensus genotypic
definition of Bennett et al.,17 including major RVP-RAMs
L100I+K103N, Y181C/I/V, Y188L, and M230L, and minor
RPV-RAMs L100I, K103S, V106A, V179F, and G190A/E/S.
The origin of E138A in subtype C-infected treatment-
naive patients was further investigated by phylogenetic
analysis and transmission ratio calculation. Specifically,
control sequences were selected using two different ap-
proaches. First, a BLAST search was performed to identify
the 10 most similar sequences to each subtype C-infected
treatment-naive patient included in this study, and their
treatment status was retrieved from the original publications.
Second, sequence data from treatment-experienced patients
infected with subtype C were collected from the Portuguese
and Leuven cohorts. HIV-1 subtype was confirmed as de-
scribed above and duplicate or clonal sequenceswere removed,
resulting in a dataset of 1,121 sequences. SDRM-related posi-
tions as well as the E138 codon were excluded from the
alignment. For phylogenetic analysis, two separate approaches
were used. First, a maximum likelihood tree was built using
RaxML, including all 1,121 sequences in the analysis. Second,
to evaluate the reproducibility of a monophyletic cluster of
sequences containing E138A, 20 maximum likelihood trees
with each including 200 sequences randomly selected from
this large dataset were constructed using PhyML.18 The
transmission ratio of E138A was calculated by dividing its
prevalence in treatment-naive patients by the prevalence
in treatment-experienced patients and interpreted following
Winand et al.19
Data were analyzed using the package R, with a level of
significance set at 5% and Benjamini–Hochberg correction
for multiple testing.20
Results
Genotypic information from 4,631 treatment-naive pa-
tients revealed one or more major RPV-RAMs in 4.6%
(n = 213) of patients, predominantly as a single mutation
(4.1%, n = 189), but also within a combination of two (0.5%,
n = 22) or three major mutations (0.04%, n = 2). Furthermore,
at least one minor RPV-RAM was present in 18.4% (n = 851)
of patients, with one (16.4%, n = 761), two (1.4%, n= 64), and
three, or more minor mutations (0.6%, n = 26). In total, 21.5%
(n = 997) of the patients presented at least one major and/or
minor RPV mutation. Figure 1 shows the prevalence of in-
dividual RPV-RAMs. The most prevalent major RPV-RAM
was E138A (3.2%, n = 146), occurring in 69% of all patients
with ‡1 major RPV-RAM, followed by K101E (0.5%,
n = 24). Minor RPV-RAMs V179I (5.7%, n= 266), V106I
(4.9%, n = 227), and V90I (3.0%, n = 137) occurred most.
Major signature NRTI mutations against TDF and FTC
M184V (0.8%, n = 35), M184I (0.07%, n = 3), K65R (0.07%,
n = 3), and K70E (0.04%, n = 2) were rarely observed.
When averaged over the three interpretation systems, viral
susceptibility to the STR and RPVwas predicted as preserved
in 94.0% – 1.0% and 95.0%– 0.7% of the patients, respec-
tively, indicating that loss in viral susceptibility to the STR
was largely attributable to RPV resistance.
An impact of HIV-1 natural diversity was evaluated by
comparing the distribution of RPV-RAMs and the predicted
activity across HIV-1 subtypes and CRFs (Table 1). Patients
were predominantly infected with HIV-1 subtype B (n= 2,110,
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45.6%) and subtype G (n= 1,345, 29.0%), followed by CRF
02_AG (n= 451, 9.7%), subtype C (n= 345, 7.5%), A1
(n= 194, 4.2%), F1 (n= 132, 2.9%), and CRF 01_AE (n= 54,
1.2%). The prevalence of ‡1 major or ‡1 minor RPV-RAMs
was significantly different across subtypes (chi-square test,
p< .001). The highest prevalence of major RPV-RAMs was
observed for subtypes C (12.5%) and F1 (6.8%), largely ex-
plained by the subtype-specific occurrence of E138A with,
respectively, 11.3% and 6.1% (Table 1). A variable prevalence
of minor RPV-RAMs was observed, with minor RPV-RAMs
V90I, A98G, V106I, and V179D/E/I/T differing significantly
across subtypes, when corrected for multiple testing. A dis-
crepancy in the proportion of patients scored susceptible to
RPV was also observed (Table 1). Viral susceptibility was
particularly reduced in patients infected with subtypes C or F1,
respectively, only 86.8%– 0.8% and 90.7%– 4.4% of patients
scored susceptible to RPV.
RPV susceptibility in subtype C-infected patients differed
according to geographic origin of sampling, with 84.3%–1.1%
of patients from Portugal who scored susceptible compared to
95.0%– 0.0% of patients from Belgium (Table 1), which was
largely explained by a prevalence of RPV-RAM E138A of,
respectively, 13.2% and 5.0% ( p= .044). Subtype F1-infected
patients displayed a lower proportion that was estimated sus-
ceptible (90.7%) together with high between-algorithm vari-
ability (4.4%).A higher prevalence of E138Awas also observed
in subtype F1-infected patients from Portugal (7.1%), explain-
ing that low proportion of patients scored susceptible
(92.0%– 0.0%). Subtype F1-infected patients from Belgium
however lacked E138A, but they still displayed a lower average
susceptibility score (82.5%– 30.1%) mainly attributable to the
minor RVP-RAM A98G (52.6%). This minor RPV-RAM is
however only scored by the HIVdb algorithm, but not by ANRS
or Rega, with only 47.4% of patients estimated susceptible by
HIVdb.
Evidence of transmitted drug resistancewas observed in 401
patients (8.7%), with RPV-RAMs Y181C, Y188L, K103S,
V106A, V179F, and G190A/S detected as SDRMs. When
excluding these patients, one ormoremajor RPV-RAMs could
still be detected in 3.4% of the remaining 4,230 study patients
and at least one minor RPV-RAM in 16.6%, while preserved
susceptibility to RPV remained in 96.0%– 1.0% of patients.
The frequency of major RPV-RAM E138A in this population
was 3.1% compared to 4.2% in the patient population with
SDRMs, although strongly varying according to geography
and subtype (Table 2). Strikingly, among 116 subtype C-
infected treatment-experienced patients from Portugal, the
RPV-RAM E138A could be detected in 11 patients (9.5%),
compared to 35 treatment-naive patients (13.2%), resulting
into a transmission ratio of 1.39.
To investigate whether a founder effect contributed to the
propagation of this polymorphism, a set of 1,121 subtype C
sequences was compiled, which included the most similar
subtype C sequences, determined as described in the Mate-
rials and Methods section. Phylogenetic analysis of the 1,121
subtype C-infected patient population revealed that a large
FIG. 1. Prevalence of indi-
vidual major (left) and minor
(right) rilpivirine resistance-
associated mutations (RPV-
RAMs).
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Table 1. Frequency of Rilpivirine Mutations Across Subtypes
n % A1 B C F1 G 01_AE 02_AG
Patients
All 4,631 100 4.2 45.6 7.5 2.9 29.0 1.2 9.7
Portugal 3,916 100 3.5 43.6 6.8 2.9 33.9 0.1 9.3
Belgium 715 100 7.8 56.8 11.2 2.7 2.2 7.1 12.2
‡1 major
All 213 4.6 3.1 4.4 12.5 6.8 3.1 1.9 4.2
Portugal 187 4.8 3.6 4.4 14.7 8.0 3.2 0.0 4.7
Belgium 26 3.6 1.8 4.4 5.0 0.0 0.0 2.3 2.0
E138A
All 146 3.2 3.1 2.8 11.3 6.1 1.8 1.8 1.8
Portugal 124 3.2 3.6 2.6 13.2 7.1 1.8 0.0 2.2
Belgium 22 3.1 1.8 3.9 5.0 0.0 0.0 2.0 0.0
‡1 minor
All 851 18.4 62.4 20.1 8.4 29.5 10.6 33.3 1.8
Portugal 686 17.5 63.0 20.2 10.5 25.6 10.3 66.7 15.9
Belgium 165 23.0 60.7 19.4 1.3 52.6 37.5 31.3 21.8
V90I
All 137 3.0 1.5 4.1 0.3 1.5 0.8 0.0 7.3
Portugal 101 2.6 1.5 3.8 0.4 1.8 0.7 0.0 6.0
Belgium 36 5.0 1.8 5.4 0.0 0.0 12.5 0.0 12.6
A98G
All 32 0.7 0.5 0.6 1.7 7.6 0.1 0.0 0.4
Portugal 22 0.6 0.7 0.7 2.3 0.0 0.1 0.0 0.5
Belgium 10 1.4 0.0 0.0 0.0 52.6 0.0 0.0 0.0
V106I
All 227 4.9 1.0 7.6 0.0 5.3 3.3 7.4 1.8
Portugal 207 5.3 0.0 8.6 0.0 6.2 3.4 0.0 1.9
Belgium 20 2.8 0.0 3.7 0.0 0.0 0.0 7.8 1.1
V179I
All 266 5.7 59.3 4.0 3.2 13.6 0.7 18.5 4.0
Portugal 192 4.9 60.1 3.5 4.2 15.9 0.7 33.4 3.0
Belgium 74 10.4 57.1 6.4 0.0 0.0 0.0 17.6 8.0
V179D
All 50 1.1 1.0 1.9 0.6 2.3 0.1 3.7 0.0
Portugal 39 1.0 0.7 1.9 0.8 2.7 0.0 0.0 0.0
Belgium 11 1.5 1.8 1.7 0.0 0.0 6.3 3.9 0.0
V179E
All 78 1.7 0.5 1.0 0.3 0 3.6 1.9 1.1
Portugal 75 1.9 0.7 1.1 0.4 0.0 3.7 0.0 1.4
Belgium 3 0.4 0.0 0.5 0.0 0.0 0.0 2.0 0.0
V179T
All 1 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0
Portugal 1 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0
Belgium 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Active RPV
Mean – SD
All — 95.0 – 0.7 96.6– 0.6 95.1 – 0.7 86.8– 0.8 90.7 – 4.4 96.8 – 0.2 98.1 – 0.0 95.4 – 0.3
Portugal — 94.8 – 0.5 96.1– 0.4 95.1 – 0.8 84.3– 1.1 92.0 – 0.0 96.7 – 0.2 100– 0.0 94.9 – 0.3
Belgium — 95.7 – 1.0 97.6– 1.0 95.4 – 0.3 95.0– 0.0 82.5 – 30.1 100– 0.0 98.0 – 0.0 97.7 – 0.0
ANRS
All 4,416 95.4 96.9 95.6 87.2 93.2 96.9 98.1 95.6
Portugal 3,727 95.2 96.4 95.6 84.9 92.0 96.8 100 95.1
Belgium 689 96.3 98.2 95.6 95.0 100 100 98.0 97.7
HIVdb
All 4,366 94.3 95.8 94.3 85.8 85.6 96.6 98.1 95.1
Portugal 3,690 94.2 95.7 94.1 83.0 92.0 96.6 100 94.5
Belgium 676 94.5 96.4 95.1 95.1 47.4 100 98.0 97.7
Rega
All 4,413 95.3 96.9 95.5 87.2 93.2 96.9 98.1 95.6
Portugal 3,724 95.1 96.4 95.4 84.9 92.0 96.8 100 95.1
Belgium 689 96.4 98.2 95.6 95.0 100 100 98.0 97.7
The distribution of HIV-1 subtypes among the 4,631 treatment-naive patients is indicated, with for each subtype, the proportion (%) of
patients displaying ‡1 major RPV-RAMs, ‡1 minor RPV-RAMs, single RPV-RAMs, and predicted activity to RPV.
Single mutations were only listed when their prevalence significantly differed across subtypes. Estimated drug activity is shown for each
individual genotypic resistance interpretation algorithm (ANRS V24, Rega V9.1.0 and HIVdb V7.0.1) and the mean of estimated
proportion of each resistance interpretation algorithm together with the SD.
HIV-1, human immunodeficiency virus type-1; RPV-RAMs, rilpivirine resistance-associated mutations; SD, standard deviation.
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number of Portuguese treatment-naive patients with E138A
formed a monophyletic cluster (Supplementary Fig. S1; Sup-
plementary Data are available online at www.liebertpub.com/
aid). Since this cluster was not supported by a large bootstrap
support, we used subsampling to evaluate the reproducibility of
this cluster. Twenty separate phylogenetic analyses, each con-
taining a subsample of 200 patients of the initial dataset, dem-
onstrated a consistent monophyletic grouping of this E138A
cluster among all 20ML trees (100%),with an aLRTsupport for
this cluster above 0.8 in 16 trees (80%) (Data not shown).
Discussion
The latest NNRTI RPV is an attractive first-line option for
treatment of HIV-1 infection due to its favorable tolerability
and dosing, but its use should be guided by resistance testing at
baseline as for other antiviral drugs, especially NNRTIs.1,21
Using a large population of treatment-naive HIV-1 patients,
we report reduced RPV susceptibility at baseline estimated
in*5%ofHIV-1 treatment-naive patients. However, variable
prevalence of RPV-RAMswas detected whenHIV-1 subtypes
were evaluated separately, with subtypes C and F1 showing a
higher prevalence of reduced baseline susceptibility to RPV.
Specifically, subtype C treatment-naive patients in our da-
tasets displayed an increased prevalence of RPV-RAM
E138A, which when present alone confers intermediate or
high-level resistance by all three algorithms. This natural
polymorphism is known to occur in varying frequencies ac-
cording to viral subtype and is previously shown to have a
higher prevalence in subtype C patients compared to subtype B
patients.6 In our study, subtype F1 strains circulating in the
Portuguese HIV-1 epidemic also showed an increased preva-
lence of this polymorphism, while subtype F1 patients in
Belgium displayed an increased prevalence ofmutationA98G.
Importantly, the RPV-RAM A98G is only assigned an inter-
mediate resistance score for RPV by the HIVdb algorithm and
is not considered by the ANRS and Rega algorithms.
The findings of our study are in large agreement with a
similar study by Lambert-Niclot et al. that observed a prev-
alence of 4.6% for major RPV-RAMs and 19.9% for any
RPV mutation in 1,729 drug-naive patients, of which 4.9%
were scored resistant by ANRS.4 They also reported a higher
prevalence of RPV genotypic resistance in pooled non-B
subtype-infected patients compared to subtype B-infected
patients, without a stratification by subtypes, however. Fur-
thermore, trends in RPV-RAMs prevalence across subtypes
observed in our study were highly comparable with mutation
frequencies according to subtype reported by the Stanford
HIV Drug Resistance Database.22
Importantly, our study shows that the prevalence of E138A
and A98G is highly determined by geographical compart-
mentalization of subtype epidemics, with a higher prevalence
of E138A in subtype C and F1 patients from Portugal and a
higher prevalence of A98G in subtype F1 patients from
Belgium. These observations suggest founder effects boost-
ing local transmission of these mutations, an HLA impact for
the selection of these mutations in each population, and/or
differences in selective pressure caused by different treat-
ment strategies between countries.23
Phylogenetic analysis of subtype C sequences supported the
hypothesis that a founder effect in the Portuguese treatment-
naive patients explains the high prevalence of E138A in Por-
tugal. Furthermore, a transmission ratio of 1.39 was detected
for E138A, indicating that high levels of transmission between
treatment-naive patients contribute to its higher prevalence.
This finding suggests that the origin of E138A in Portugal is
most probably not the treated population and confirms its
forward transmission among treatment-naive patients.19 De-
spite its reported selection by ART, the E138A mutation is not
included in the surveillance mutation list of Bennett et al. due
to the polymorphic nature of RT position 138.17 A prevalent
E138A in treatment-naive patients could have accompanied
transmitted DRMs, however, our results strongly suggest that
the reduced viral susceptibility to RPV and in particular the
increased E138A prevalence in a geographic and subtype-
dependent manner resulted from the propagation of a natural
polymorphism following a founder event.
Regarding the origin of an increased E138A presence in
treatment-naive patients, a distinction between original trans-
mission from treated patients and increased prevalence of a
natural polymorphism after a founder effect can have impor-
tant implications for the treatment of HIV-1 infected patients.
If E138A predominantly results from transmission from trea-
ted patients, its high prevalence would largely coincide with
regions with substantial ART coverage and could be addressed
by targeted intervention strategies or optimized treatment
Table 2. Frequency of E138A and Transmitted Drug Resistance
Subtype
Belgium (n= 715) Portugal (n= 3,916)
TDR (%)
E138A (%)
TDR (%)
E138A (%)
WT TDR WT TDR
All 9.9 3.3 1.4 8.4 3.0 4.9
A1 1.8 1.8 0 3.6 3.8 0.0
B 14.5 4.3 1.7 10.9 2.8 0.6
C 3.8 5.2 0.0 6.0 11.7 37.5
F1 5.3 0.0 0.0 5.3 7.5 0.0
G 6.3 0.0 0.0 6.9 1.3 8.8
AE 3.9 2.0 0.0 0.0 0.0 0.0
AG 4.6 0.0 0.0 7.1 2.1 3.9
The frequency of TDR and of RPV-RAM E138A in patients with (TDR) or without SDRMs (WT), according to subtype and
geographical origin of the patient (Belgium–Leuven Cohort, Portugal, Portuguese Cohort).
SDRM, surveillance drug resistance mutation; TDR, transmitted HIV-1 drug resistance; WT, wild-type.
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policies in addition to resistance testing that is usually re-
commended before ART initiation in these regions.
This study, however, finds that natural variability and
founder effects can boost the natural occurrence of E138A,
suggesting that even regions with low ART coverage can
display a high prevalence of RPV resistance, with potentially
devastating implications when RPV-based first-line treat-
ment is initiated in the absence of routine resistance testing of
treatment-naive patients.1 In addition to supporting large-
scale analyses of RPV genotypic resistance in treatment-
naive patients,22 the significance of our findings should also
be further elucidated in localized epidemics characterized by
similar and other subtypes.
In this study, we show a high prevalence of reduced sus-
ceptibility to RPV at baseline in all subtypes, but with a sig-
nificant variability both between HIV-1 subtypes and between
local epidemics. These findings have an important impact for
the use of RPV as first-line treatment. Loss of RPV activity
directly affects the success of this low genetic barrier drug
combination, but also limits future treatment options due to
extensive cross-resistance to other NNRTIs andmost likely also
to other NRTIs upon failure of this regimen. In the context of
such a high prevalence of reduced susceptibility to RPV at
baseline, even in patients without TDR, drug resistance testing
at baseline should be considered extremely important before
starting treatment with this NNRTI.
Furthermore, the fact that the prevalence of RPV-RAMs
differed between local subtype epidemics indicates a geo-
graphical compartmentalization of such variants that should
be further investigated and monitored. Finally, the finding of
discrepancies between drug resistance algorithms indicates
the need for a better consensus on the impact of RPV-RAMs.
In summary, our results indicate that drug resistance to RPV
should be more thoroughly investigated. Until then, drug
resistance testing at baseline is crucial for patients initiating
therapy with an RPV containing regimen.
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